

**Amendments to the Claims:**

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A process comprising:  
\_\_\_\_\_ applying an ophthalmic medicine or ophthalmic solution comprising a  
complex nutritive base to an eye of a human or an animal,  
\_\_\_\_\_~~The use of a complex nutritive base in an aqueous medium, the said-base~~  
comprising at least a multiplicity of amino acids, vitamins, trace elements, and metallic salts  
and being free of any cellular growth factor or any biological extract of animal or cellular  
origin or any pharmaceutically active principle,~~as an ophthalmologic medicine or ophthalmic~~  
~~solution for application in external contact with the eye in man or in animals.~~
2. (Currently Amended) A process for treating an item that is designed to come  
into external contact with a cornea of an eye of a human or an animal, the process comprising:  
\_\_\_\_\_ treating the item with a treatment product comprising~~The use of a complex~~  
~~nutritive base in an aqueous medium, the said-base~~ comprising at least a multiplicity of amino  
acids, vitamins, trace elements, and metallic salts and being free of any cellular growth factor  
or any biological extract of animal or cellular origin or any pharmaceutically active principle;  
~~as a treatment product for the storage, preservation, transport, or placement of items or~~  
~~prostheses, such as contact lenses, which are designed to come into external contact with the~~  
~~cornea of the eye in man or in animals.~~
3. (Currently Amended) The use-process as claimed in claim 1, ~~characterized in~~  
~~that wherein~~ the ophthalmologic medicine or ophthalmologic solution consists of a trophic  
composition in an aqueous medium comprising the complex nutritive base, an inhibitor of  
collagenases of the human or animal corneal epithelium, and a promoter of neocollagen  
synthesis.

4. (Currently Amended) The ~~use-process~~ as claimed in claim 2, ~~characterized in that wherein~~ the treatment product consists of a trophic composition in an aqueous medium comprising the complex nutritive base, an inhibitor of collagenases of the human or animal corneal epithelium, and a promoter of neocollagen synthesis.

5. (Currently Amended) The ~~use-process~~ as claimed in claim 3, ~~characterized in that wherein~~ the trophic composition is formulated so as to establish a pH between 7.3 and 7.5 and an osmolarity between 300 and 350 Osm.

6. (Currently Amended) The ~~use-process~~ as claimed in claim 5, ~~characterized in that wherein~~ the inhibitor of collagenases is ~~chosen~~ selected from the group comprising consisting of cysteine, N-acetylcysteine, and EDTA calcium salt.

7. (Currently Amended) The ~~use-process~~ as claimed in claim 5, ~~characterized in that wherein~~ the inhibitor of collagenases is N-acetylcysteine.

8. (Currently Amended) The ~~use-process~~ as claimed in claim 5, ~~characterized in that wherein~~ the inhibitor of collagenases represents at most 5% ~~and preferably between 0.05 and 0.5%~~ by weight of the trophic composition.

9. (Currently Amended) The ~~use-process~~ as claimed in claim 5, ~~characterized in that wherein~~ the promoter of neocollagen synthesis is proline or hydroxyproline.

10. (Currently Amended) The ~~use-process~~ as claimed in claim 5, ~~characterized in that wherein~~ the promoter of neocollagen synthesis represents at most 0.5% ~~and preferably 0.004%~~ by weight of the trophic composition.

11. (Currently Amended) The ~~use-process~~ as claimed in claim 5, ~~characterized in that it wherein~~ the ophthalmologic solution comprises hyaluronic acid and/or a salt of hyaluronic acid in a total proportion by weight of the trophic composition of at most 0.1% and preferably 0.07%.

12. (Currently Amended) The ~~use-process~~ as claimed in claim 5, ~~characterized in that wherein~~ the trophic composition includes a preservative in a proportion by weight of the ~~said composition~~ of at most 0.0001%.

13. (Currently Amended) The ~~use-process~~ as claimed in claim 12, ~~characterized in that wherein~~ the preservative is polyhexanide or polyhexamethylene biguanide.

14. (Currently Amended) The ~~use-process~~ as claimed in claim 12, ~~characterized in that wherein~~ the trophic composition ~~corresponds to the formula described by Table 2 in the description.~~ comprises the following components:

<u>Component</u>	<u>Concentration (mg/L)</u>
Water	q.s.
Sodium chloride	6800
Glutamine	1754.4
Sodium bicarbonate	1160
Glucose	1080
Arginine HCl	421.4
Sodium acetate	300
Disodium phosphate	284
Leucine	131.2
Serine	126.1
Mg chloride	120.0
K chloride	112
Valine	70.3
Sodium pyruvate	55
Lysine HCl	54
Histidine HCl	50

Cysteine HCl	42
Adenine	24
Threonine	24
Ca chloride	20.05
Inositol	18
Glutamic acid	14.8
Asparagine	14.2
Methionine	13.5
Tyrosine	11.7
Phenylalanine	10.0
Tryptophan	9.3
Alanine	9.2
Glycine	7.6
Isoleucine	6.0
Aspartic acid	4.0
Sodium sulfate	3.4
Ferrous sulfate	0.003
Folic acid	0.8
Thymidine	0.73
Cyanocobalamin	0.41
Calcium antiothenate	0.3
Thiamine HCl	0.3
Thioctic acid	0.3
Zinc sulfate	0.144
Sodium silicate	0.142

Pyrodixine HCl	0.06
Niacinamide	0.04
Riboflavin	0.3
Biotin	0.02
Copper sulfate	0.003
Ammonium molybdate	0.00120
Ammonium vanadate	0.003
Mn chloride	0.00002
Sodium hyaluronate	70
Polyhexanide or polyhexamethylene biguanide	0.1
n-acetylcysteine	500
Hydroxyproline or praline	35.

15. (Currently Amended) The ~~use-process~~ as claimed in claim 1, ~~characterized in that wherein~~ the ophthalmologic medicine or ophthalmologic solution is in liquid form or in dry form, ~~that is to say~~ for reconstitution with an aqueous medium.

16. (Currently Amended) The ~~use-process~~ as claimed in claim 2, ~~characterized in that wherein~~ the treatment product is in liquid form or in dry form, ~~that is to say~~ for reconstitution with an aqueous medium.

17. (Currently Amended) The ~~use-process~~ as claimed in claim 1, ~~characterized in that wherein~~ the ophthalmologic medicine or ophthalmologic solution is in ~~the a~~ form selected from the group consisting of drops or regenerating tears, or comfort drops, or eyewash, or and solution.

18. (Currently Amended) The ~~use-process~~ as claimed in claim 1, ~~characterized in that wherein~~ the ophthalmic solution is a comfort solution.

19. (Currently Amended) The ~~use-process~~ as claimed in claim 4, ~~characterized in that~~ wherein the trophic composition is formulated so as to establish a pH between 7.3 and 7.5 and an osmolarity between 300 and 350 Osm.